Biogenerics Announces Share Dividend Ratio From WW Oil and Gas Inc.admin
Biogenerics Limited announced that its shareholders of record as of January 2, 2007 will receive 1(one) WW Oil and Gas Inc. restricted common share for every 19(nineteen) Biogenerics shares held. The shares will be paid out on January 30, 2007. The special dividend shares will be mailed out to qualified shareholders of record without any action(s) required by eligible recipients.
About Biogenerics Limited
Biogenerics is a diversified investment venture capital firm focused on exploiting and distributing domestic oil and gas reserves. Biogenerics also has joint venture activities with Tyche Energy Inc and Hydroslotter Corp.
WW Oil & Gas Inc., established in 2005, is in the business of acquiring leases and oil and gas related assets. Such acquisitions are for the purposes of development, exploration, and exploitation. The company currently has several exploitation projects encompassing four oil and gas leases in the San Juan Basin area of New Mexico and Oklahoma. Comprehensive drill programs are being developed for full exploitation of these projects. ConocoPhillips, XTO Energy and British Petroleum are among those companies active in the San Juan Basin.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this release that are forward-looking statements are based on current expectations and assumptions that are subject to known and unknown risks, uncertainties, or other factors which may cause actual results, performance, or achievements of the company to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Actual results could differ materially because of factors such as the effect of general economic and market conditions, entry into markets with vigorous competition, market acceptance of new products and services, continued acceptance of existing products and services, technological shifts, and delays in product development and related product release schedules, any of which may cause revenues and income to fall short of anticipated levels. All information in this release is as of the date of this release. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.
CONTACT: Biogenerics Limited Corporate Inquiries James Lancaster, CEO (903)-561-2446 Investor Relations